323 related articles for article (PubMed ID: 22406621)
21. Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity.
Heo KS; Chang E; Takei Y; Le NT; Woo CH; Sullivan MA; Morrell C; Fujiwara K; Abe J
Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):321-9. PubMed ID: 23202365
[TBL] [Abstract][Full Text] [Related]
22. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
Goto E; Tomita A; Hayakawa F; Atsumi A; Kiyoi H; Naoe T
Blood; 2011 Aug; 118(6):1600-9. PubMed ID: 21613260
[TBL] [Abstract][Full Text] [Related]
23. Arkadia, a novel SUMO-targeted ubiquitin ligase involved in PML degradation.
Erker Y; Neyret-Kahn H; Seeler JS; Dejean A; Atfi A; Levy L
Mol Cell Biol; 2013 Jun; 33(11):2163-77. PubMed ID: 23530056
[TBL] [Abstract][Full Text] [Related]
24. The promyelocytic leukemia protein stimulates SUMO conjugation in yeast.
Quimby BB; Yong-Gonzalez V; Anan T; Strunnikov AV; Dasso M
Oncogene; 2006 May; 25(21):2999-3005. PubMed ID: 16501610
[TBL] [Abstract][Full Text] [Related]
25. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
[TBL] [Abstract][Full Text] [Related]
26. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
27. ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator.
Karvonen U; Jääskeläinen T; Rytinki M; Kaikkonen S; Palvimo JJ
J Mol Biol; 2008 Oct; 382(3):585-600. PubMed ID: 18656483
[TBL] [Abstract][Full Text] [Related]
28. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4.
González-Prieto R; Cuijpers SA; Kumar R; Hendriks IA; Vertegaal AC
Cell Cycle; 2015; 14(12):1859-72. PubMed ID: 25895136
[TBL] [Abstract][Full Text] [Related]
29. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
30. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
Ablain J; Leiva M; Peres L; Fonsart J; Anthony E; de Thé H
J Exp Med; 2013 Apr; 210(4):647-53. PubMed ID: 23509325
[TBL] [Abstract][Full Text] [Related]
31. Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination.
Yeung PL; Denissova NG; Nasello C; Hakhverdyan Z; Chen JD; Brenneman MA
J Cell Biochem; 2012 May; 113(5):1787-99. PubMed ID: 22213200
[TBL] [Abstract][Full Text] [Related]
32. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus.
Müller S; Matunis MJ; Dejean A
EMBO J; 1998 Jan; 17(1):61-70. PubMed ID: 9427741
[TBL] [Abstract][Full Text] [Related]
33. Protein inhibitor of activated STAT 1 (PIAS1) is identified as the SUMO E3 ligase of CCAAT/enhancer-binding protein β (C/EBPβ) during adipogenesis.
Liu Y; Zhang YD; Guo L; Huang HY; Zhu H; Huang JX; Liu Y; Zhou SR; Dang YJ; Li X; Tang QQ
Mol Cell Biol; 2013 Nov; 33(22):4606-17. PubMed ID: 24061474
[TBL] [Abstract][Full Text] [Related]
34. The transcriptional activity of co-activator AIB1 is regulated by the SUMO E3 ligase PIAS1.
Li S; Yang C; Hong Y; Bi H; Zhao F; Liu Y; Ao X; Pang P; Xing X; Chang AK; Xiao L; Zhang Y; Wu H
Biol Cell; 2012 May; 104(5):287-96. PubMed ID: 22283414
[TBL] [Abstract][Full Text] [Related]
35. Identification of a non-covalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation.
Mascle XH; Lussier-Price M; Cappadocia L; Estephan P; Raiola L; Omichinski JG; Aubry M
J Biol Chem; 2013 Dec; 288(51):36312-27. PubMed ID: 24174529
[TBL] [Abstract][Full Text] [Related]
36. Roles of the SUMO-related enzymes, PIAS1, PIAS4, and RNF4, in DNA double-strand break repair by homologous recombination.
Han MM; Hirakawa M; Yamauchi M; Matsuda N
Biochem Biophys Res Commun; 2022 Feb; 591():95-101. PubMed ID: 35007836
[TBL] [Abstract][Full Text] [Related]
37. PIAS1 and TIF1γ collaborate to promote SnoN SUMOylation and suppression of epithelial-mesenchymal transition.
Chanda A; Ikeuchi Y; Karve K; Sarkar A; Chandhoke AS; Deng L; Bonni A; Bonni S
Cell Death Differ; 2021 Jan; 28(1):267-282. PubMed ID: 32770107
[TBL] [Abstract][Full Text] [Related]
38. β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.
Satow R; Shitashige M; Jigami T; Fukami K; Honda K; Kitabayashi I; Yamada T
Gastroenterology; 2012 Mar; 142(3):572-81. PubMed ID: 22155184
[TBL] [Abstract][Full Text] [Related]
39. The SUMO ligase PIAS1 regulates UV-induced apoptosis by recruiting Daxx to SUMOylated foci.
Sudharsan R; Azuma Y
J Cell Sci; 2012 Dec; 125(Pt 23):5819-29. PubMed ID: 22976298
[TBL] [Abstract][Full Text] [Related]
40. CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Choi S; Baldini C; Konstantinidou G; Pandolfi PP
Mol Cell Biochem; 2008 Sep; 316(1-2):149-54. PubMed ID: 18566754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
